Research programme: immune checkpoint inhibitors - Innate Pharma

Drug Profile

Research programme: immune checkpoint inhibitors - Innate Pharma

Alternative Names: anti-CD73 antibodies; IPH 53

Latest Information Update: 21 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innate Pharma
  • Developer Innate Pharma; Paoli-Calmettes-institute
  • Class Antibodies; Antineoplastics
  • Mechanism of Action CD antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 06 Jul 2015 Innate Pharma and Paoli Calmettes Institute collaborate on translational research for immune checkpoint inhibitor antibodies for Haematological malignancies
  • 06 Jul 2015 Early research in Haematological malignancies in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top